Would you offer immunotherapy first line for patients with adrenocortical carcinoma outside of a clinical trial?  

I have not been using ICI as first-line therapy for ACC unless there are concerns for tolerability to EDP. We also do usually not include mitotane in EDP in patients with nonfunctional ACCs. Given the somewhat promising activity of pembrolizumab in ACC, it is a very reasonable second-line choice as ...